Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Jockeys For Advantage In Wake Of Tysabri Withdrawal, Avonex Warning

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Tysabri withdrawal effects: GlaxoSmithKline, Antisense Therapeutics halt MS drug Phase II trials, citing identical mechanism of action. Teva, Serono, Schering jockey for advantage over Biogen Idec following additional reports of PML in Tysabri recipients, addition of Avonex liver warning

You may also be interested in...



Biogen Idec Bolsters MS, Oncology Pipeline Via PDL Co-Development Pact

Biogen Idec will leverage its multiple sclerosis and oncology franchises to co-develop Protein Design Labs’ daclizumab and volociximab for MS and cancer applications under a deal worth up to $800 mil.

FDA Safety Request Delays Novartis Phase III Program For MS Agent FTY720

Novartis is delaying the start of Phase III clinical trials for its oral multiple sclerosis treatment FTY720 until the fourth quarter following a request for a safety analysis from FDA

Tysabri Deaths In Crohn’s Studies Suggest "Plausible" Link – FDA Review

Biogen Idec/Elan Tysabri deaths in Crohn’s trials suggest a “plausible mechanisitic link” to the monoclonal antibody, review documents state. While FDA did not note a clear connection to natalizumab, the agency found several deaths in Crohn’s disease trials to be “of concern.” Review documents do not discuss any cases of progressive multifocal leukoencephalopathy, which led to drug’s market withdrawal

Related Content

Topics

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel